Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
Liraglutide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
ClinicalTrials.gov (3)
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Phase NA · COMPLETED · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase PHASE1 · RECRUITING · Sponsor: Novo Nordisk A/S
PubMed (14)
Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.
Naunyn-Schmiedeberg's archives of pharmacology · 2026 Jul 18 · DOI: 10.1007/s00210-026-05646-6
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Multiple sclerosis and related disorders · 2026 Jul 10 · DOI: 10.1016/j.msard.2026.107388
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction.
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026 Jul 21 · DOI: 10.1186/s43044-026-00767-y
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026 Jul 21 · DOI: 10.1111/dom.71138
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Indian journal of orthopaedics · 2026 Jul · DOI: 10.1007/s43465-025-01614-z
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026 Jul 20 · DOI: 10.1177/87551225261466571
Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111313
GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.
Frontiers in neurology · 2026 · DOI: 10.3389/fneur.2026.1858507
Clinical efficacy of liraglutide combined with pioglitazone in obese polycystic ovary syndrome and its effects on the serum chemerin/visfatin ratio.
American journal of translational research · 2026 · DOI: 10.62347/WNDZ4386
A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100304
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363
Circulating levels of PYY are increased in individuals with bile acid diarrhoea.
The Journal of clinical endocrinology and metabolism · 2026 Jul 24 · DOI: 10.1210/clinem/dgag295